| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/22/1999 | WO1999019478A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 04/22/1999 | WO1999019477A1 Cadherin derived growth factor and the application thereof |
| 04/22/1999 | WO1999019476A2 NON-MAMMALIAN MESODERM INDUCTION EARLY RESPONSE (nm-MIER) GENE FAMILY |
| 04/22/1999 | WO1999019473A1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/22/1999 | WO1999019471A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
| 04/22/1999 | WO1999019466A2 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
| 04/22/1999 | WO1999019463A1 Anticoagulant test |
| 04/22/1999 | WO1999019462A1 Enhanced immunogenic cell populations prepared using h2 receptor antagonists |
| 04/22/1999 | WO1999019457A1 Regulators of ucp3 gene expression |
| 04/22/1999 | WO1999019362A1 BISPECIFIC MOLECULES DIRECTED TO TUMOR ASSOCIATED GLYCOPROTEIN-72 AND Fc RECEPTOR |
| 04/22/1999 | WO1999019359A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle |
| 04/22/1999 | WO1999019357A2 Cell regulatory genes, encoded products, and uses related thereto |
| 04/22/1999 | WO1999019356A1 Trivalent thrombin inhibitor |
| 04/22/1999 | WO1999019354A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 04/22/1999 | WO1999019352A2 Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids |
| 04/22/1999 | WO1999019351A1 Novel npy family member |
| 04/22/1999 | WO1999019350A1 Use of elicitins as lipid carriers |
| 04/22/1999 | WO1999019349A1 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 04/22/1999 | WO1999019347A1 Synthetic genes with immunomodulatory effects |
| 04/22/1999 | WO1999019346A1 Dipeptides for the treatment of diseases related to the biological effect of endothelin |
| 04/22/1999 | WO1999019339A1 53 human secreted proteins |
| 04/22/1999 | WO1999018999A1 Compositions for controlling bacterial colonization |
| 04/22/1999 | WO1999018997A1 Potentiator for antibody against lymphoid tumor |
| 04/22/1999 | WO1999018996A1 Enterococcus antigens and vaccines |
| 04/22/1999 | WO1999018995A1 Immunogenic peptides from the hpv e7 protein |
| 04/22/1999 | WO1999018994A1 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
| 04/22/1999 | WO1999018993A1 Ameliorant for hepatitis c remedial effect and application thereof |
| 04/22/1999 | WO1999018992A1 Oromucosal cytokine compositions and uses thereof |
| 04/22/1999 | WO1999018991A1 Materials and methods relating to cartilage repair |
| 04/22/1999 | WO1999018990A1 The il-1 receptor related protein 3 (il-1rrp3) |
| 04/22/1999 | WO1999018989A1 F-box proteins and genes |
| 04/22/1999 | WO1999018988A1 Process to identify a sexual response-stimulating substance |
| 04/22/1999 | WO1999018987A1 Ligand binding site of rage and uses thereof |
| 04/22/1999 | WO1999018986A1 Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
| 04/22/1999 | WO1999018983A1 Composition and method for treating an encephalomyelopathic, demyelinating or autoimmune disease |
| 04/22/1999 | WO1999018981A1 Implants comprising combinations of allogeneic cells for use in cancer treatment |
| 04/22/1999 | WO1999018980A1 Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
| 04/22/1999 | WO1999018979A1 Storage-stable hemoglobin composition |
| 04/22/1999 | WO1999018976A1 Therapeutic methods comprising use of a neuregulin |
| 04/22/1999 | WO1999018961A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus |
| 04/22/1999 | WO1999018956A1 12(s)-hete receptor blockers |
| 04/22/1999 | WO1999018945A1 Method of building and maintaining bone |
| 04/22/1999 | WO1999018909A2 Interferon-gamma regulatory factors |
| 04/22/1999 | WO1999018801A1 Methods and compositions for the treatment of autoimmune disease using heat shock proteins |
| 04/22/1999 | WO1999018799A1 Treatment of neoplasms with viruses |
| 04/22/1999 | WO1999018798A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 04/22/1999 | WO1999018781A1 Dipeptide apoptosis inhibitors and the use thereof |
| 04/22/1999 | WO1999013886B1 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications |
| 04/22/1999 | WO1999006561A3 Chemokine receptor ccr8 dna and uses thereof |
| 04/22/1999 | WO1999005264A3 Production of human mutant proteins in human cells by homologous recombination |
| 04/22/1999 | WO1999004806A9 Methods and compositions for inhibiting angiogenesis |
| 04/22/1999 | WO1999003454A9 Biodegradable macromers for the controlled release of biologically active substances |
| 04/22/1999 | WO1999002565A3 Agent for the treatment and/or prophylaxis of microcirculation disorders |
| 04/22/1999 | WO1999002146A8 Amino acid derivatives |
| 04/22/1999 | WO1999001556A3 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES |
| 04/22/1999 | WO1999001118A3 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 04/22/1999 | WO1998059055A3 Detoxifying proteins |
| 04/22/1999 | WO1998058957A3 Disulfide cross-linked glycoprotein hormone analogs, their preparation and use |
| 04/22/1999 | WO1998053068A9 Smad7 and uses thereof |
| 04/22/1999 | WO1998052590A3 Improved delivery of disease modifiers |
| 04/22/1999 | WO1998047921A9 Mammalian cytokines; related reagents and methods |
| 04/22/1999 | WO1998045328A3 Compositions and methods for the treatment and diagnosis of breast cancer |
| 04/22/1999 | WO1998044021A9 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
| 04/22/1999 | WO1997038729A8 In vivo gene transfer methods for wound healing |
| 04/22/1999 | DE19746173A1 Tumor vaccine based on tumor antigens comprises a slow-release system of gamma-interferon (IFN-gamma |
| 04/22/1999 | DE19745583A1 New actagardine derivatives with extra N-terminal amino acid |
| 04/22/1999 | CA2315244A1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/22/1999 | CA2312906A1 Oromucosal cytokine compositions and uses thereof |
| 04/22/1999 | CA2308122A1 Anticoagulant test |
| 04/22/1999 | CA2308118A1 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 04/22/1999 | CA2308009A1 Novel npy family member |
| 04/22/1999 | CA2307328A1 Cell division regulators |
| 04/22/1999 | CA2307208A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 04/22/1999 | CA2306991A1 Ligand binding site of rage and uses thereof |
| 04/22/1999 | CA2306823A1 Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides |
| 04/22/1999 | CA2306476A1 Enterococcus antigens and vaccines |
| 04/22/1999 | CA2306459A1 Compositions for controlling bacterial colonization |
| 04/22/1999 | CA2306455A1 Human receptor proteins; related reagents and methods |
| 04/22/1999 | CA2306453A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 04/22/1999 | CA2306448A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
| 04/22/1999 | CA2306444A1 Inhibition of human immunodeficiency virus (hiv-1) replication |
| 04/22/1999 | CA2306443A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
| 04/22/1999 | CA2306440A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle |
| 04/22/1999 | CA2306344A1 Method of building and maintaining bone |
| 04/22/1999 | CA2306228A1 Therapeutic methods comprising use of a neuregulin |
| 04/22/1999 | CA2306206A1 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
| 04/22/1999 | CA2306062A1 Methods and compositions for the treatment of autoimmune disease using heat shock proteins |
| 04/22/1999 | CA2305713A1 Apo-3 ligand |
| 04/22/1999 | CA2305698A1 Human progesterone receptor complex p23-like protein |
| 04/22/1999 | CA2305690A1 53 human secreted proteins |
| 04/22/1999 | CA2304374A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus |
| 04/22/1999 | CA2303935A1 12(s)-hete receptor blockers |
| 04/22/1999 | CA2303844A1 Regulators of ucp3 gene expression |
| 04/22/1999 | CA2275135A1 Phosphodiesterase 8a |
| 04/22/1999 | CA2248762A1 Antisense oligodeoxynucleotides regulating expression of tnf-.alpha. |
| 04/21/1999 | EP0909822A1 Novel antitumor compounds and process for producing the same |
| 04/21/1999 | EP0909820A2 Histidine kinase from Staphylococcus pneumoniae |
| 04/21/1999 | EP0909819A1 Streptococcus pneumoniae Isoleucyl tRNA synthetase (Iles)[6.1.1.5.] |
| 04/21/1999 | EP0909818A1 Valyl tRNA synthetase (EC 6.1.1.9) from Streptococcus pneumoniae |
| 04/21/1999 | EP0909817A1 Uses of gro genes and proteins |